Compounds and methods for inhibiting emt pathways to treat cancer, organ fibrosis and metabolic disorders
AssigneesUniversity of Pittsburgh—Of the Commonwealth System of Higher Education, Universite Le Havre Normandie
InventorsAbdelhadi Rebbaa, Sebastien Comesse, Adam Daich, Martin Lawson, Catalin Pintiala
Life of this patent
Estimating the term…
Abstract
A compound, or a pharmaceutically acceptable salt or isomer thereof, of Formula I: wherein R is hydrogen, alkyl, substituted alkyl, alkenyl, or substituted alkenyl; R1 is hydrogen, alkoxy, or substituted alkoxy; R2 is hydrogen, alkyl, or substituted alkyl; and R3 is hydrogen, alkyl, or substituted alkyl.
Claims25
1-15. (canceled)
A method for treating an epithelial-mesenchymal transition-associated disorder or an adenosine monophosphate-activated protein kinase-associated disorder in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or stereoisomer thereof, of Formula I:
- wherein R is hydrogen, alkyl, substituted alkyl, alkenyl, or substituted alkenyl;
- R1 is hydrogen, alkoxy, or substituted alkoxy;
- R2 is hydrogen, alkyl, or substituted alkyl;
- and
- R3 is hydrogen, alkyl, or substituted alkyl.
A method of inhibiting at least one of a Hippo, Wnt, and TGF beta pathway in a subject, comprising administering to the subject a compound, or a pharmaceutically acceptable salt or stereoisomer thereof, of Formula I:
- wherein R is hydrogen, alkyl, substituted alkyl, alkenyl, or substituted alkenyl;
- R1 is hydrogen, alkoxy, or substituted alkoxy;
- R2 is hydrogen, alkyl, or substituted alkyl;
- and
- R3 is hydrogen, alkyl, or substituted alkyl.
A method of inhibiting an epithelial-mesenchymal transition in a cell, comprising contacting the cell with a compound, or a pharmaceutically acceptable salt or stereoisomer thereof, of Formula I:
- wherein R is hydrogen, alkyl, substituted alkyl, alkenyl, or substituted alkenyl;
- R1 is hydrogen, alkoxy, or substituted alkoxy;
- R2 is hydrogen, alkyl, or substituted alkyl;
- and
- R3 is hydrogen, alkyl, or substituted alkyl.
A method of activating an adenosine monophosphate-activated protein kinase in a cell, comprising contacting the cell with a compound, or a pharmaceutically acceptable salt or stereoisomer thereof, of Formula I:
- wherein R is hydrogen, alkyl, substituted alkyl, alkenyl, or substituted alkenyl;
- R1 is hydrogen, alkoxy, or substituted alkoxy;
- R2 is hydrogen, alkyl, or substituted alkyl;
- and
- R3 is hydrogen, alkyl, or substituted alkyl.
Dependencies are inferred from the claim text.